Suominen Corporation
25.2.2021 15:31:31 CET | Globenewswire | Press release
Suominen Corporation February 25, 2021 at 4:30 p.m. (EEST)
Suominen Corporation - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Helsky, Petri
Position: Chief Executive Officer
Issuer: Suominen Corporation
LEI: 743700Z1BNFYR9PRDF52
Notification type: INITIAL NOTIFICATION
Reference number: 743700Z1BNFYR9PRDF52_20210225081652_2
____________________________________________
Transaction date: 2021-02-25
Venue: OFF-EXCHANGE TRANSACTIONS (XOFF)
Instrument type: SHARE
ISIN: FI0009010862
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION
Transaction details
(1): Volume: 12,002 Unit price: N/A
Aggregated transactions
(1): Volume: 12,002 Volume weighted average price: N/A
SUOMINEN CORPORATION
For more information, please contact
Emilia Peltola, Vice President, Communications & IR, Suominen Corporation, tel. +358 50 540 9747
Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2020 were EUR 458.9 million and we have nearly 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
